Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02106351 · ClinicalTrials.gov registry record · Phase 3
Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children
A Phase 3 study, sponsored by Ipsen.
- Completed
- Registry status
- Phase 3
- Development phase
- 212
- Enrollment target
NCT02106351 is a Phase 3 study that has completed, run by Ipsen. The registered enrollment target is 212 participants.
The verdict
NCT02106351, a Phase 3 study, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 212 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of multiple doses of Dysport used in the treatment of upper limb spasticity (altered skeletal muscle performance) in children with cerebral palsy (CP).
Interventions
- BIOLOGICAL Botulinum toxin type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2014-04 |
| Est. Completion | 2018-09-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02106351
The ClinicalTrials.gov registry entry for NCT02106351 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Botulinum toxin type A is the first listed.
NCT02106351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02106351 about?
NCT02106351 is a clinical study titled "Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children". The purpose of this study is to assess the efficacy and safety of multiple doses of Dysport used in the treatment of upper limb spasticity (altered skeletal muscle performance) in children with cerebral palsy (CP).
What is the current status of trial NCT02106351?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 212 participants. The study started on 2014-04. Estimated completion is 2018-09-04.
What interventions are being tested in trial NCT02106351?
The interventions under investigation include: Botulinum toxin type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT02106351?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.